Comparative Pharmacology
Head-to-head clinical analysis: KETOZOLE versus MONISTAT DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOZOLE versus MONISTAT DERM.
KETOZOLE vs MONISTAT-DERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketoconazole is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This leads to increased membrane permeability and cell death.
Miconazole inhibits fungal lanosterol 14α-demethylase, a cytochrome P450 enzyme, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
200 mg orally once daily with food.
Topical: Apply once daily to affected areas for 2-4 weeks. Vaginal: One 200 mg suppository at bedtime for 3 days, or one 100 mg suppository at bedtime for 7 days, or one 1200 mg suppository as a single dose.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.5–3.5 hours). Clinically, duration of antifungal effect extends beyond plasma half-life due to persistent tissue levels.
Terminal elimination half-life is approximately 24–30 hours, supporting twice-daily or once-daily dosing for dermatologic infections.
Primarily hepatic metabolism; renal excretion of unchanged drug <1%. Biliary/fecal excretion accounts for ~20-35% of metabolites.
Primarily fecal (biliary) elimination as unchanged drug and metabolites; <1% renal excretion of unchanged drug.
Category C
Category C
Antifungal
Antifungal